

hims & hers

SUPPLEMENTAL PRESENTATION

Investor Presentation

May 2025



Safe Harbor Statement

This presentation has been prepared by Hims & Hers Health, Inc. ("we," "us," "our," "Hims & Hers," or the "Company").

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "assume," "may," "will," "likely," "potential," "projects," "predicts," "continue," "goal," "strategy," "future," "forecast," "target," "outlook," "project," or "should," or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line revenue growth and profitability and our ability to attain our 2025 and 2030 financial targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, the solutions accessible on our platform, and our infrastructure, and the underlying assumptions with respect to the foregoing; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, strategy, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions, changes in our product or offering mix, the timing and market acceptance of any new products or offerings, the timing and anticipated effect of any pending or recently completed acquisitions, the success of our business model, our market opportunity, our ability to scale our business and expand internationally, the growth of certain of our specialties, our ability to innovate on and expand the scope of our offerings and experiences, including through the use of data analytics and artificial intelligence, our ability to reinvest into the customer experience, and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of litigation or governmental actions in relation to any such legal and regulatory requirements. These statements are based on management's current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this presentation are based on our current expectations, assumptions and beliefs concerning future developments and their


potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission (the "Commission").

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this presentation are made only as of the date on which the statements are made. We undertake no obligation to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.





We include statements and information in this presentation concerning our industry and the markets in which we operate, including our market opportunity, which are based on information from independent industry organizations and other third-party sources (including industry publications, surveys and forecasts). While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified any third-party information and such information is inherently imprecise.

Feeling good in your body
& mind transforms how
you show up in life

That's why we're on a
mission to help the world
feel great through the
power of better health



Our platform democratizes access to high-quality personalized solutions and service quality levels, by leveraging technology to deliver a frictionless experience



Our team is led by a visionary founder, with support from a leadership team that has scaled disruptive companies



Andrew Dudum

Chief Executive Officer & Co-Founder




Yemi Okupe

Chief Financial Officer




Nader Kabbani

Chief Operating Officer¹




Soleil Boughton

Chief Legal Officer




Mike Chi

Chief Commercial Officer




Dr. Pat Carroll

Chief Medical Officer & Director



Khobi Brooklyn

Chief Corporate Affairs Officer



Dan Kenger

Chief Design Officer

ATOMIC

Uber

amazon

G

ZOLA

W

Nike

gin lane

Braintree

symbotic

JONES DAY

INTERMIX

Hartford HealthCare

TESLA

pattern

G

lexport

GILT

DARTMOUTH

Aurora

We believe we have the ability to help over 100 million consumers across specialties we serve

→ 90%

as much as 90% of applicable population yet to seek treatment in some conditions

Through normalizing and innovating, our platform can unlock solutions for millions of potential customers



Sexual Health

80M+ est. US population




Dermatology

80M+ est. US population




Mental Health

100M+ est. US population



Weight Loss

100M+ est. US population



Coming Soon¹

Testosterone

Launching in 2025²

Menopause

Launching in 2025²

Longevity

Sleep


Preventative Medicine

Our platform has evolved to reach a broader audience by delivering exceptional service and offering access to data-driven personalized solutions

EVOLUTION OF PLATFORM


Awareness + On-Demand Access

- Users can connect with a provider to address concerns, typically within 24-48 hours
- Transparent pricing helps ensure customers know exactly what they pay for
- Hims & Hers helps destigmatize emotionally sensitive conditions



Exceptional Service + Convenience

- Reliable tech enables care from home via web, iOS, and Android
- A variety of tools streamline care, offering virtually unlimited provider access



Data-informed Personalization

- Data-driven, personalized solutions cater to common customer needs
- Millions of data points inform providers to help drive positive outcomes



60%+

of subscribers using a personalized product


Our platform positions us to partner with industry leaders to become a curator of the best solutions and services for consumers

History of leveraging partners to strengthen our ecosystem, bringing additional value to our customers

Long-term collaboration with Novo Nordisk launched April 2025

Pairs our **customer-centric** platform with Novo Nordisk's innovative pipeline

Developing a **blueprint for future partnerships**, to deliver access to quality care at scale






Our Strategy



Our value proposition strengthens with each new subscriber



Brand investment positions Hims & Hers to become synonymous with high quality personalized treatment



Presence in Most Culturally Relevant Moments



Thought Leaders Across Our Specialties







Drive Awareness for Critical Health Issues



Distinct Brands with Distinct Approaches



Technology platform provides consumers with convenient and rapid access to personalized care



Proprietary EMR

Mitigates administrative burden for providers

Consumer tools

Unlock fast service from the comfort of their home

Operational tools

Elevate consumer experience and operational efficiency

MedMatch by Hims & Hers

Facilitates data-driven recommendations

Over time, we've launched innovative solutions and services, drawing in a broader audience, strengthening retention, and reshaping industry norms



Differentiated Form Factors

Hard Mints by Hims

Chewable ED solution with multiple treatment options



Hair Blends by Hers


Custom vitamin, biotin, and minoxidil combinations including topicals



Personalized Dosages

Oral Weight Loss by Hims & Hers

Personalized compounded oral solutions



Injectable Weight Loss by Hims & Hers

Personalized compounded GLP-1 solutions



Multi-Condition Offerings


Sex Rx + Hair Health by Hims

Multi-action solution for ED and hair loss





Balance Blend Rx by Hims & Hers

2-in-1 solution for mental health combining an SSRI with vitamins and supplements



Increasing precision in Sexual Health allows us to evolve with our customers as their needs change



The breadth of our weight loss offering continues to expand, addressing a variety of subscriber profiles



Wegovy® through NovoCare®

In long-term clinical trial
Avg >30lbs¹ weight lost or 15% of initial body weight

Launched April 2025

BMI of 30+ or 27+ with one or more comorbidities



Liraglutide

In long-term clinical trial
Avg 18lbs¹ weight lost or 8% of initial body weight

Launched March 2025

BMI of 30+ or 27+ with one or more comorbidities



Oral Weight Loss

After 8 weeks
Avg 8lbs² weight lost or 4% of initial body weight

Launched December 2023

Adaptable across BMI ranges



Personalized Semaglutide Dosage

Requires in depth documented clinical need

After 8 weeks
Avg 12lbs² weight lost or 5% of initial body weight

Launched July 2024

BMI of 30+ or 27+ with one or more comorbidities

An ecosystem that provides subscribers value beyond medication is proving to be vital across our specialties



Diagnostics

- MedMatch by Hims & Hers to support provider diagnosis and treatment plans
- Personalized titration schedules across offerings
- Vitamin & supplement support to address deficiencies

Services and Tools

- Trackers for water intake, nutrition, movement, and sleep
- Meal replacement options
- Treatment and nutrition plans
- Workout guides

Follow-up Care & Support

- 24/7 provider access allows frequent provider support
- High provider engagement has helped drive **>70% retention¹** in Weight Loss after 3 months

Our multi-year investments in our facilities drive our personalization capabilities




Scaling fulfillment operations

90%+*

fulfillment through affiliated facilities

*Refers to US orders as of 3/31/25



Clinical excellence drives high quality outcomes & reinforces trust in our brand



Transparency

Certificates of Analysis for GLP-1s




100% board-certified¹



Fast & convenient




on avg. from visit submit to treatment²



Clinical standards

Systematic monitoring of clinical standards




Manufacturing and supply chain

FDA and state regulated facilities and third-party testing




Specialized training

Platform-integrated training on specialized topics and evidence-based medicine enable expert input at scale.




High-quality service levels and personalized solutions are driving a leadership position

Share of Observed Total Customers



Share of Observed Total Sales



■ Hims & Hers Health, Inc.

■ Thirty Madison Inc.

■ Roman Health Ventures Inc.

■ Noom Inc.

■ Curology Inc.

■ BetterHelp

Source: Bloomberg Second Measure LLC

Disclaimer: Bloomberg Second Measure LLC ("BSM LLC") is a wholly owned subsidiary of Bloomberg L.P. BSM LLC receives de-identified consumer transaction data under license agreements with data providers, which BSM LLC then normalizes and aggregates to create analytics. BSM LLC delivers to subscribers revenue and transaction analytics and insights on thousands of public and private equities. These analytics are derived from consumer transaction data (i.e., credit and debit card transactions) solely from US credit card and debit cards and bank accounts. BSM LLC also uses United States census data. BSM LLC data analytics draw from a sample of credit and debit card purchases made by U.S. consumers. Observed sales data may vary from actual company reported sales data. For each company, the predictive accuracy of BSM LLC's estimates will typically vary over time. There is no guarantee that accuracy levels, trends or correlations will recur for any company in the future. Note: Represents market share across Sexual Health, Dermatology, Mental Health, and Weight Loss (as applicable).



Long-Term Vision



Execution and foundational capabilities that are positioned to scale give us confidence in achieving new 2030 financial targets

2030 Revenue
of at least

\$6.5B+


2030 Adjusted EBITDA¹
of at least

\$1.3B+


(1) This is a non-GAAP financial measure. Please refer to page 36 for definitions. We have relied upon the exception in Regulation G and have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net income or loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net income or loss. See page 38 for additional important information regarding Adjusted EBITDA.

Our long-term roadmap will be driven by an ongoing focus across five key growth levers


Deepening personalization




Expansion into new emotionally resonant specialties




Elevated follow up care



Global expansion of our platform



Strategic partnerships will expand ecosystem



Recent acquisitions strengthen our value proposition in the near term, and provide a foundation for our long-term vision

Outsourcing Facility

| Our first **503B** compounding outsourcing facility acquired in **Sept. 2024**

| Positions us to launch into new specialties where sterile facilities are required in the future



Lab Facility

| At-home **lab testing** facility acquired in **Feb. 2025**

| Supports deeper subscriber relationships and more innovative treatments

| More robust insights can accelerate AI efforts, expanding access to high quality care



Peptide Facility

| U.S.-based peptide facility acquired in **Feb. 2025**

| Further verticalizes and strengthens our domestic supply chain


| Opportunities in peptide innovation, including in pain management, longevity, and muscle recovery



Lab testing capabilities can democratize access to deeper health insights

Lab testing makes personalized care more accessible


At-home test kit



Lab testing



We expect to build a broad selection of lab tests and insights over time



Data readout

Iron

Lower than normal

Nutrient Panel

April 8, 2025

Omega-3 Total

In-range

Nutrient Panel

March 12, 2025

Customers can then take action via a broad assortment of personalized medications¹ and supplements

Broad assortment of solutions



2025 priorities center on 5 key areas to achieve our long-term vision

1

Long-term Leadership Position in Weight Loss

Expand portfolio of solutions:

| Integration of Novocare

| Launch of Liraglutide

Verticalization of 503A and 503B facilities

Leverage data / AI

2

Integrate Lab Diagnostic Capabilities

Deepen platform value proposition through lab testing:

| Health insights

| More powerful data for AI engine

| Deeper customization

3

Extend Breadth of Personalized Solutions

Expand capacity for broader form factors and permutations through:

| Automation

| Launch of New Facility

4

Build Foundation for New Specialty Launches

Launch of low testosterone & menopause support

Conduct R&D for new specialties

R&D for peptides

5

Expand Technological Capabilities

Onboard CTO

Expand MedMatch by Hims & Hers

Build infrastructure to leverage deeper AI

Financials



Our recurring revenue model sets a foundation for strong revenue growth and margin expansion

- 90%+ recurring revenue¹
- Mid-70s gross margin profile
- <1 year pay back period²

38%
Subscriber
Growth³

1.7M
Q1'24

2.4M
Q1'25

111%
Revenue
Growth

\$278M
Q1'24


\$586M
Q1'25

4%
Adjusted
EBITDA Margin
Expansion⁴

12%
Q1'24

16%
Q1'25

The launch of new specialties, and the introduction of personalized products and services has allowed us to scale



Note: Menopause and low testosterone are not currently available on our platform, and are expected to launch in 2025. Such expected launches, subject to certain assumptions and factors, some of which may be outside of our control and as such may be subject to change. (1) This contemplates our 2025 revenue guidance of \$2.3-\$2.4 billion.

Our subscriber¹ count and customer engagement drive revenue growth

..... NUMBER OF SUBSCRIBERS¹

Acquisition

Multi-channel
brand development



Retention

Customer
experience



Engagement

Multi-month
adoption

Brand
ambassadors



High clinical
excellence



Partnerships





Specialized
content & tools



..... REVENUE PER SUBSCRIBER¹


..... PERSONALIZATION

Revenue growth driven by expanding subscriber base, further complemented by increasing revenue per average subscriber




(1) "Subscribers" are customers who have one or more subscriptions pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. (2) "Monthly online revenue per average subscriber" is defined as online revenue divided by "average subscribers", which amount is then further divided by the number of months in a period. "Average subscribers" are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

Strong unit economics have provided a foundation to scale with confidence




¹(1) Payback period defined as the time it takes quarterly cumulative online gross profit generated by Hims & Her online customers to exceed the quarterly customer acquisition cost to acquire those customers. Cumulative online gross profit represents total online revenue less costs directly attributable to the products shipped and services rendered, including product costs, packaging materials, shipping costs, labor costs directly related to revenue generating activities including medical consultation services and manufacturing labor, and overhead costs associated with manufactured products; (2) Paid marketing expenses (also referred to as customer acquisition expenses in our most recently filed Annual Report on Form 10-K and our most recently filed Quarterly Report on Form 10-Q) represent total advertising and media costs associated with our efforts to acquire new customer, promote our brands, and build awareness for our products and services. Paid marketing expenses include advertising in digital media, social media, television, radio, out-of-home media, and various other media outlets.

Scalability of model is driving continued Adjusted EBITDA margin expansion as topline momentum remains strong



(1) This is a non-GAAP financial measure. Please refer to pages 36 and 38 – 39 for definitions and reconciliations to the corresponding U.S. GAAP financial measure. (2) As of March 31, 2025, cash, cash equivalents, and short-term investments total \$323 million with no outstanding debt. Reference our most recently filed Quarterly Report on Form 10-Q.

Strong free cash flow enabling ability to scale the business while maintaining a strong balance sheet



2025 outlook anticipates strong top line growth and continued leverage

	Q2 2025	FY 2025	2025 underlying themes
Revenue	\$530M - \$550M	\$2.3B - \$2.4B	<ul style="list-style-type: none"> 1 85%+ <u>long-term retention</u>²
YoY growth	68% - 74%	56% - 63%	<ul style="list-style-type: none"> 2 Expanding portfolio of <u>personalized offerings</u>
Adj. EBITDA ¹	\$65M - \$75M	\$295M - \$335M	<ul style="list-style-type: none"> 3 Strong unit economics with <u>payback period</u>³ < 1 year
Adj. EBITDA margin ¹	12% - 14%	13% - 14%	<ul style="list-style-type: none"> 4 Evolving model drives inherent <u>marketing efficiencies</u>
			<ul style="list-style-type: none"> 5 Weight loss revenue of at least <u>\$725 million in 2025</u>⁴

(1) This is a non-GAAP financial measure. Please refer to page 36 for definitions. We have relied upon the exception in Regulation G and have not reconciled forward-looking Adjusted EBITDA or forward-looking Adjusted EBITDA margin to their most directly comparable U.S. GAAP measures, net income or loss and net income margin or net loss margin, respectively, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net income or loss and future net income margin or net loss margin. See page 38 for additional important information regarding Adjusted EBITDA and Adjusted EBITDA margin. (2) Online revenue retention from subscriptions with a tenure of at least 2 years. (3) Payback period defined as the time it takes quarterly cumulative online gross profit generated by Hims & Hers online customers to exceed the quarterly customer acquisition costs to acquire those customers. Online gross profit represents total online revenue less costs directly attributable to the products shipped and services rendered, including product costs, packaging materials, shipping costs, labor costs directly related to revenue generating activities including medical consultation services and manufacturing labor, and overhead costs associated with manufactured products. (4) On February 21, 2025, the FDA resolved the semaglutide shortage, which has constrained and is expected to continue to constrain our ability to continue providing access to compounded semaglutide on our platform. The FDA does not limit compounding to drug shortages, and we believe there are paths to continue offering access to certain compounded GLP-1s after the period of FDA enforcement discretion has ended following resolution of the shortage, consistent with the statutory exemptions from the new drug approval requirements. As such, we intend to continue expanding our weight loss offerings and serving our Subscribers with a wide range of weight loss solutions.

Capital Investments in 2025 will focus on unlocking higher quality and more personalized care for millions of individuals




Facility and capacity expansion

- | Scale AZ facility
- | Expand sterile capabilities
- | Increase automation to unlock customer value




Rapid scaling of data intelligence layer

- | Increased R&D efforts in peptide facility
- | Acceleration of lab diagnostic distribution



Acceleration of new specialties

- | Position to launch new, more complex specialties
- | Hormonal therapies like low testosterone and menopausal support



Increased breadth of personalization

- | New form factors and more multi-condition treatments
- | Incorporation of lab diagnostics supports more comprehensive care

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), Adjusted EBITDA margin (which is a non-GAAP ratio), and Free Cash Flow (which is a non-GAAP financial measure) each as defined below. We use Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow is helpful to our investors as they are used by management in assessing the health of our business, our operating performance, and our liquidity.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.


Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. "Adjusted EBITDA" is defined as net income (loss) before stock-based compensation, income taxes, depreciation and amortization, acquisition and transaction-related costs (which includes (i) consideration paid for employee compensation with vesting requirements incurred directly as a result of acquisitions, inclusive of revaluation of earn-out consideration recorded in general and administrative expenses prior to 2024, and (ii) transaction professional services), legal settlement expenses that are considered non-recurring, impairment of long-lived assets, change in fair value of liabilities, and interest income and expense, net. "Adjusted EBITDA margin" is defined as Adjusted EBITDA divided by revenue.

Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net income (loss) and other U.S. GAAP results.

Free Cash Flow is a key performance measure that our management uses to assess our liquidity. Because Free Cash Flow facilitates internal comparisons of our historical liquidity on a more consistent basis, we use this measure for business planning purposes. "Free Cash Flow" is defined as net cash provided by operating activities, less purchases of property, equipment, and intangible assets and investment in website and mobile application development and internal-use software in investing activities.

Some of the limitations of Free Cash Flow include (i) Free Cash Flow does not represent our residual cash flow for discretionary expenditures and our non-discretionary commitments, and (ii) Free Cash Flow includes capital expenditures, the benefits of which may be realized in periods subsequent to those in which the expenditures took place. In evaluating Free Cash Flow, you should be aware that in the future we will have cash outflows similar to the adjustments in this presentation. Our presentation of Free Cash Flow should not be construed as an inference that our future results will be unaffected by these cash outflows or any unusual or non-recurring items. When evaluating our performance, you should consider Free Cash Flow in addition to, and not as a substitute for, other financial performance measures, including our net cash provided by operating activities and other U.S. GAAP results.

Appendix



Net Income (Loss) to Adjusted EBITDA Reconciliation

(\$ thousands, unaudited)	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25
Revenue	\$207,912	\$226,699	\$246,619	\$278,171	\$315,648	\$401,556	\$481,139	\$586,010
Net income (loss)	(\$7,157)	(\$7,567)	\$1,245	\$11,128	\$13,297	\$75,588	\$26,025	\$49,485
Stock-based compensation	\$16,845	\$17,277	\$17,791	\$19,032	\$24,042	\$24,899	\$24,349	\$24,858
Provision (benefit) for income taxes	(\$13)	\$651	\$951	\$1,275	\$127	(\$51,995)	(\$3,734)	\$11,010
Depreciation and amortization	\$2,377	\$2,363	\$2,658	\$3,001	\$3,643	\$4,383	\$6,061	\$8,276
Acquisition and transaction-related costs	\$583	\$1,280	\$507	\$376	\$590	\$858	\$2,155	\$24
Legal settlement	–	–	–	–	–	–	\$2,008	–
Impairment of long-lived assets	–	–	–	–	\$75	\$39	–	–
Change in fair value of liabilities	\$173	\$588	\$19	–	–	–	–	–
Interest income and expense, net	(\$2,173)	(\$2,342)	(\$2,601)	(\$2,540)	(\$2,431)	(\$2,637)	(\$2,741)	(\$2,596)
Adjusted EBITDA	\$10,635	\$12,250	\$20,570	\$32,347	\$39,307	\$51,096	\$54,123	\$91,057
Net income (loss) as a % of revenue	(3%)	(3%)	1%	4%	4%	19%	5%	8%
Adjusted EBITDA margin	5%	5%	8%	12%	12%	13%	11%	16%

Net Cash Provided By Operating Activities to Free Cash Flow Reconciliation

(\$ thousands, unaudited)	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25
Net cash provided by operating activities	\$16,826	\$25,191	\$21,983	\$25,838	\$53,594	\$85,267	\$86,385	\$109,090
Less: purchases of property, equipment, and intangible assets in investing activities	(\$4,677)	(\$3,277)	(\$8,631)	(\$10,581)	(\$3,212)	(\$3,342)	(\$24,520)	(\$55,327)
Less: investment in website development and internal-use software in investing activities	(\$2,187)	(\$2,643)	(\$2,567)	(\$3,377)	(\$2,814)	(\$2,539)	(\$2,365)	(\$3,711)
Free Cash Flow	\$9,962	\$19,271	\$10,785	\$11,880	\$47,568	\$79,386	\$59,500	\$50,052

Sources

In order of appearance:

B. Kim, S. Lee, M Jun, H. Chung, S. Oh. Perception of Hair Loss and Education Increases the Treatment Willingness in Patients With Androgenetic Alopecia: A Population-Based Study, 2018, Fig. 1B. Based on a research study with 503 patients with AGA, 92% of the patients had no past treatment.

K. Nunes, H. Labazi, and R. Webb, PubMed Central, New Insights into Hypertension-Associated Erectile Dysfunction, 2012- Guttmacher Institute, Contraceptive Use in the United States by Demographics, 2021. (Est population rounded)

American Academy of Dermatology Association website, Skin Conditions by the Numbers, Accessed February 2025; available at <https://www.aad.org/media/stats-numbers>

Quick Facts and Statistics About Mental Health. Mental Health America. Accessed February 2025. <https://mhanational.org/mentalhealthfacts>

YouGov website, Clifton Mark, 52% of the world's adults are trying to lose weight. Who are they?, 2022. Est. population calculated with Statista, Resident population of the United States by sex and age as of July 1, 2021

Adult Obesity Facts, Centers for Disease Control and Prevention, as of May 2024, available at <https://www.cdc.gov/obesity/adult-obesity-facts/index.html>

Prevalence of Overweight, Obesity, and Severe Obesity Among Adults Aged 20 and Over: United States, 1960–1962 Through 2017–2018; by Cheryl D. Fryar, M.S.P.H., Margaret D. Carroll, M.S.P.H., and Joseph Afful, M.S., Division of Health and Nutrition Examination Surveys; December 2020; available at <https://www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/overweight-obesity-adults-H.pdf>

Any anxiety disorder. Accessed February 2025. National Institute of Mental Health (NIMH); available at <https://www.nimh.nih.gov/health/statistics/any-anxiety-disorder>

Lee B, Wang Y, Carlson SA, et al. National, State-Level, and County-Level Prevalence Estimates of Adults Aged ≥ 18 Years Self-Reporting a Lifetime Diagnosis of Depression – United States, 2020. MMWR Morb Mortal Wkly Rep 2023;72:644–650.

Rosen RC. Prevalence and risk factors of sexual dysfunction in men and women. Curr Psychiatry Rep. 2000 Jun;2(3):189–95. doi: 10.1007/s11920-996-0006-2. PMID: 11122954.

Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open. 2022 Sep 1;5(9):e2231982. doi: 10.1001/jamanetworkopen.2022.31982. PMID: 36121652; PMCID: PMC9486455.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 Jul 2;373(1):11–22. doi: 10.1056/NEJMoa1411892. PMID: 26132939.